References:
1.-Cornec D, Cornec-Le Gall E, Fervenza F, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 2016;12:570-579.
2.-Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin L et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nature Rev Rheumatol 2017;13:683-692.
3.-Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA Determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2005;47:15-23.
4.-Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 1993;36:365-371.
5.-Davenport A, Lock RJ, Wallington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol 1995;15:201–207.
6.-Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med 2007;120:643.e9–643.e14.
7.-Verstockt B, Bossuyt X, Vanderschueren S, Blockmans D. There is no benefit in routinely monitoring ANCA titers in patients with granulomatosis with polyangiitis. Clin Exp Rheumatol 2015; 33: S72-S76.
8.-Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33:1101-1107.
9.-Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American college of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome. Arthritis Rheum 1990;33:1094-1100.
10.-Kyndt X, Reumaux D, Bridoux F, et al. Serial Measurements of Antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med. 1999;106:527–533.
11.-Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE et al.
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-3462.
12.-Terrier B, Saadoun D, Sène D, Ghillani P, Amoura Z, Deray G et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009;68:1564–1571.
13.-Tomasson G, Grayson PC, Mahr AD, LaValley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. Rheumatology 2012; 51: 100-109.
14.-Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 2015;26:537–542.
15.-Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015;74: 177–184.
16.-Tanna A, Guarino L, Tam FWK, Rodriquez-Cubillo B, Levy JB, Cairns TD et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant 2015;30:1185–1192.
17.-Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J. Rheumatol 2014;41:1366–1373
18.-Vizjak A, Rott T, Koselj-Kajtna M, Rozman B, Kaplan-Pavlovcic S, Ferluga D. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis 2003;41:539-549.
19.-de Joode AAE, Sanders J SF, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013; 8:1709-1717.
20.-Quintana LF, Perez NS, De Sousa E, Rodas LM, Griffiths MH, Solé M et al. ANCA serotype and histopathological classification for the prediction of renal outcome in ANCAassociated glomerulonephritis. Nephrol Dial Transplant 2014; 29:1764-1769.
21.-Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, et al. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study. Arthritis Res Ther 2015; 17: 305.
22.-Franssen CFM, Gans ROB, Arends AJ, Hageluken C, ter Wee PM, Gerlag PGG et al. Differences between anti-myeloperoxidase-and anti-proteinase 3 associated renal disease. Kidney Int 1995; 47:193–199.
23.-Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-852.
24.-Marco H, Draibe, Villacorta J, Quintana LF, Martin N, Garcia-Osuna N et al. Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement. Clinical Rheumatology. doi.org/10.1007/s10067-017-3973-3982.
25.-Guilpain P, Chereau C, Goulvestre C, Servettaz A, Montani D, Tamas N et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J 2011; 37: 1503–1513
26.Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respiratory J 2010 36: 116-121.
27.-Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)- associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014;93:340–349.
28.-Franssen CFM, Stegeman CA, Oost-Kort WW, Kallenberg CGM, Limburg PC, Tiebosch A et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 1998;9:1915-1923.
Table 1. Clinical characteristics and outcome of ANCA-associated vasculitis according to antigenic specificity.
Table 2. Clinical characteristics and outcome of ANCA-associated vasculitis according to ANCA pattern
Table 3. Variables associated with clinical relapses in GPA amd MPA
Table 4. Variables associated with clinical relapses in GPA and MPA. Multivariate analysis.
Table 5. Variables associated with worsening renal failure in anti-MPO vasculitis. Univariate analysis.
Table 6. Variables associated with worsening renal failure in anti-MPO vasculitis. Multivariate analysis
Fig 1. Clinical relapse according to ANCA pattern in GPA and MPA. A: all ANCA vasculitis; B: anti-PR3 vasculitis; C: anti-MPO vasculitis.
Fig 2. Worsening renal failure according to ANCA pattern in GPA or MPA anti-MPO vasculitis.